Clinical Trial Update: Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update shows ARO-ENaC was studied in healthy volunteers and patients with cystic fibrosis (Phase 1/2) and the study is terminated with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ARO-ENaC (ENaC inhibitor (epithelial sodium channel))

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Cystic Fibrosis, Pulmonary | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-12-17